Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years
03 Feb 2026
bởiAudrey Abella
In an updated analysis of the NATALEE* trial, the efficacy benefit of adjuvant ribociclib remains consistent even after the planned 3-year treatment duration for patients with HR+, ERBB2– early breast cancer (EBC).
NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years
03 Feb 2026
Serum albumin levels negatively linked to hypertension onset
02 Feb 2026
bởiStephen Padilla
Serum albumin may indirectly reduce the risk of hypertension by regulating obesity, inflammatory status, and fluid balance, suggests a study.







